Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RLMD
RELMADA THERAPEUTICS, INC.
NASDAQ
$4.43
▲ UP 1.37% (0.06)

KEY STATISTICS

Market Cap$464.14 M
52w High$8.00
52w Low$1.30
Dividend Yield—
Frequency—
P/E-4.92
Volume675.55K
Shares Out.104.89M

COMPANY

LEADERSHIP

Sergio Traversa
CHIEF EXECUTIVE
Sergio Traversa

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 20, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
17

PRICE TARGET

Target High$12.00
Target Low$10.00
Target Median$11.00
Target Consensus$11.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2019-09-30Reverse1:4
2015-08-12Reverse1:5

PRICE

$4.43 ▲ UP 1.37% (+$0.06)
OVERLAYS
$4.35$4.38$4.41$4.449:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM4.43

About Relmada Therapeutics, Inc.

https://www.relmada.com ↗

Relmada Therapeutics, a clinical-stage biotech founded in 2004 in Coral Gables, FL, develops CNS disease treatments, with its lead candidate, Esmethadone, in Phase 3 trials for major depressive disorder.

INDUSTRY

Biotechnology

A PRODUCT RELMADA THERAPEUTICS, INC. IS KNOWN FOR

NDV-01
NDV-01

NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel for NMIBC, Relmada's lead oncology program with promising Phase 2 results and planned Phase 3 trials in 2026.

COMPETITORS

COMPETITOR
CGON COMPARE
IBRX COMPARE
LIPO COMPARE
TARA COMPARE
URGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
70
LISTED HERE
15
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.2M
IWM
0.01% · 2.4M
XPH
0.68% · 936.0K
PSIL
4.43% · 560.5K
FESM
0.02% · 264.8K
DX2D.DE
0.30% · 221.0K
SBIO
0.26% · 141.5K
AVSC
0.01% · 81.7K
GSSC
0.03% · 67.8K
BBC
0.42% · 47.2K
RSSL
0.01% · 45.3K
PRFZ
0.01% · 38.2K
PILL
0.46% · 23.5K
URTY
0.01% · 3.7K
PQ
PQSG
0.16% · 721

INSTITUTIONAL OWNERSHIP

SHARES OWNED
53.73%
HOLDERS
167
TOP 12 OF 167 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
11.1M sh · $76.89M
Blackrock, Inc.
7.4M sh · $51.39M
Vr Adviser, LLC
6.8M sh · $47.36M
Adage Capital Partners Gp, L.L.C.
4.8M sh · $32.96M
Orbimed Advisors LLC
4.7M sh · $32.82M
Marshall Wace, Llp
4.5M sh · $31.19M
Millennium Management LLC
3.9M sh · $27.19M
Ikarian Capital, LLC
3.1M sh · $14.82M
Ra Capital Management, L.P.
2.9M sh · $20.51M
State Street Corp
2.5M sh · $17.42M
Geode Capital Management, LLC
2.5M sh · $17.25M
Driehaus Capital Management LLC
2.1M sh · $14.75M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2022-12-12
 Christopher L. Jacobs
Christopher L. Jacobs
Sale (Full)
2022-12-12

INSIDER TRADES

★
DIRECTOR
CASAMENTO CHARLES J
Purchase · 164.0K shares
2025-12-12
★
OFFICER: CHIEF FINANCIAL OFFICER
Shenouda Maged
Purchase · 11.7K shares
2025-12-15
★
OFFICER: CA AND CO
Ence Chuck
Purchase · 828.0K shares
2025-12-12
★
DIRECTOR
Fedeli Fabiana
Purchase · 164.0K shares
2025-12-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
2 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
IMUX$12.75COMPARE
CBUS$1.61COMPARE
VXRT$0.50COMPARE
ACRV$2.13COMPARE
ACET$9.64COMPARE
FBIO$2.71COMPARE
PMVP$1.28COMPARE
LITS$1.10COMPARE